Synchronised therapy and high-dose XXXX in proliferative @entity1988 .

@entity1 @entity1310 @entity786 @entity1252 @entity1988 @entity1011
The aim of this open study was to compare the outcomes and side effects of plasmapheresis (PP) in @entity1 with proliferative @entity1988 treated with @entity786 (Cyc) boluses. The study involved 28 consecutive @entity1 . All of the @entity1 met the ACR modified criteria for @entity1252 and underwent a qualifying renal biopsy. In group I, @entity1 were treated with synchronised therapy (PP, 50 ml/kg, followed by pulse Cyc, 750 mg/m(2), repeated monthly for 6 months), whereas in group II, they were given only intermittent Cyc boluses (at the same dosage). The data were collected in the @entity1 ' records according to a standardised protocol. @entity1 were followed-up for a mean of 4 years. The disease-free survival was analysed using Kaplan-Meier estimated survival curves ([S(t)]). At the end of the 6-month treatment period, a statistically significant number of @entity1 in group I (75%) was in complete remission in comparison to group II (31%) (P < 0.02), whereas at long-term follow-up, these percentages were similar (41% vs. 50%, P = n.s.). The main functional and immunological parameters showed a normalisation in both groups. The risk of a poor renal outcome significantly correlated with high serum @entity1011 levels at the onset of @entity1310 (P < 0.05). We documented a higher rate of infectious complications in group I. This study reports that synchronised therapy is useful in inducing a faster remission in @entity1 with proliferative @entity1988 . However, it is not superior to conventional therapy at long term follow-up analysis. Positive results should be reinforced by a long-term maintenance therapy.
